Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience

Table 2 Univariate and multivariate COX regression

Characteristics	Univariate analysis			Multivariable analysis
	HR	95%CI	P value	HR	95%CI	P value
Age	1.010	0.997 – 1.023	0.1330
Pertuzumab use	0.515	0.303 – 0.877	0.0145	0.468	0.271 – 0.809	0.0066
Positive ER status	0.722	0.531 – 0.981	0.0374	0.875	0.601 – 1.274	0.4871
Positive PR status	0.744	0.534 – 1.037	0.0806	0.770	0.511 – 1.161	0.2136
Presence of metastases
Brain	2.953	1.844 – 4.730	< 0.0001	3.620	2.229 – 5.879	< 0.0001
Lung	1.393	1.023 – 1.897	0.0352	1.520	1.107 – 2.086	0.0097
Liver	1.900	1.395 – 2.590	< 0.0001	2.051	1.495 – 2.815	< 0.0001
Bone	1.321	0.966 – 1.804	0.0808
Other sites	1.231	0.895 – 1.693	0.2007
Grade (Reference: Grade 1)
Grade 2	3.616	0.494 – 26.463	0.2056
Grade 3	2.799	0.388 – 20.202	0.3075
Race (Reference: Chinese)
Indian	1.184	0.636 – 2.204	0.5952
Malay	1.350	0.931 – 1.957	0.1135
Others	0.620	0.313 – 1.227	0.1701

Six variables were used for multivariate analyses based on the sample size. They are estrogen receptor status, progesterone receptor status, Pertuzumab use, presence of brain, lung and liver metastases. ER: Estrogen receptor; PR: Progesterone receptor.